Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
121 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016', provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia - The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects - The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 B-Cell Chronic Lymphocytic Leukemia Overview 9 Therapeutics Development 10 Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 10 Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 11 B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 12 B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 14 B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 18 B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 20 B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 21 AB Science SA 21 Amgen Inc. 22 Celgene Corporation 23 Dynavax Technologies Corporation 24 Eisai Co., Ltd. 25 Elsalys Biotech SAS 26 F. Hoffmann-La Roche Ltd. 27 iDD biotech SAS 28 Immunomedics, Inc. 29 Johnson & Johnson 30 Juno Therapeutics Inc. 31 Molecular Templates Inc. 32 Noxxon Pharma AG 33 Ono Pharmaceutical Co., Ltd. 34 Regeneron Pharmaceuticals, Inc. 35 TheraMAB LLC 36 Unum Therapeutics, Inc. 37 B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 202-b - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AB-8779 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 alemtuzumab biosimilar - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 AMG-319 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ATTCK-20 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Cellular Immunotherapy for Hematological Malignancies - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Cellular Immunotherapy to Target CD19 for Cancer - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 E-7449 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 IDD-001 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 IDD-002 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 JNJ-64052781 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 lenalidomide - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 MAT-303 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MT-3724 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 olaptesed pegol - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 ONO-4059 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 REGN-1979 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 SD-101 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 TAB-08 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 tocilizumab - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 90 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 114 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 117 B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 118 Featured News & Press Releases 118 Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement 118 Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 118 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121
List of Tables Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2016 10 Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2016 21 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H1 2016 22 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H1 2016 23 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H1 2016 24 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H1 2016 25 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1 2016 26 B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 27 B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2016 28 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2016 29 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H1 2016 30 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H1 2016 31 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H1 2016 32 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2016 33 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 34 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 35 B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H1 2016 36 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Stage and Target, H1 2016 40 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2016 90 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2016 114 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H1 2016 115 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H1 2016 116 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2016 117
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.